Myeloproliferative neoplasm secondary prevention: Difference between revisions
No edit summary |
No edit summary |
||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 3: | Line 3: | ||
{{CMG}}{{AE}} {{MJK}} | {{CMG}}{{AE}} {{MJK}} | ||
==Overview== | ==Overview== | ||
Secondary prevention measures include routine monitoring of laboratory values, including [[complete blood count]] (CBC) and metabolic panel. | |||
== | ==Secondary Prevention== | ||
Secondary prevention measures include routine monitoring of laboratory values, including [[complete blood count]] (CBC) and metabolic panel. The frequency of laboratory checks varies depending on the severity disease and the clinical assessment.<ref name="cancergov">National Cancer Institute. Physician Data Query Database 2015.http://www.cancer.gov/types/myeloproliferative</ref> | |||
==References== | ==References== | ||
| Line 14: | Line 14: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
Latest revision as of 14:32, 5 November 2019
|
Myeloproliferative Neoplasm Microchapters |
|
Differentiating myeloproliferative neoplasm from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Myeloproliferative neoplasm secondary prevention On the Web |
|
American Roentgen Ray Society Images of Myeloproliferative neoplasm secondary prevention |
|
Myeloproliferative neoplasm secondary prevention in the news |
|
Directions to Hospitals Treating Myeloproliferative neoplasm |
|
Risk calculators and risk factors for Myeloproliferative neoplasm secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2]
Overview
Secondary prevention measures include routine monitoring of laboratory values, including complete blood count (CBC) and metabolic panel.
Secondary Prevention
Secondary prevention measures include routine monitoring of laboratory values, including complete blood count (CBC) and metabolic panel. The frequency of laboratory checks varies depending on the severity disease and the clinical assessment.[1]
References
- ↑ National Cancer Institute. Physician Data Query Database 2015.http://www.cancer.gov/types/myeloproliferative